[Congressional Record Volume 154, Number 153 (Thursday, September 25, 2008)]
[Senate]
[Pages S9483-S9484]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]




                         ADDITIONAL STATEMENTS

                                 ______
                                 

                    RECOGNIZING ROY SILVERSTEIN, M.D

 Mr. BROWN. Mr. President, I would like to take a few moments 
to recognize the achievements of Dr. Roy Silverstein, an Ohioan who has 
dedicated his professional life to biomedical research and medicine.
  Dr. Silverstein is currently chairman of the Department of Cell 
Biology and vice chair for translational research at the Lerner 
Research Institute, as well as professor of molecular medicine at the 
Cleveland Clinic Lerner College of Medicine at Case Western Reserve 
University.
  Having chaired multiple grant review panels and published over 100 
articles in various publications and scientific journals, Dr. 
Silverstein has accomplished an extraordinary number of professional 
milestones and achievements.
  As committee chair for the American Society of Hematology, ASH, for 
the past 4 years, Dr. Silverstein has led the society's efforts to 
educate Members of Congress about hematology and the importance of 
Federal research funding. In this capacity, Dr. Silverstein has visited 
with me and my staff to educate us about the critical issues facing 
hematologists.
  The skilled advocacy and research of Dr. Silverstein remind many of 
us in Congress of how crucial it is to keep NIH funding strong. His 
work demonstrates that NIH funding truly is a vehicle for enhancing the 
health and wellbeing of Americans. In addition to continuing his own 
research in blood clotting and bleeding disorders, Dr. Silverstein has 
also shown great commitment to educating our next generation of 
physicians and researchers. Dr. Silverstein is a superb advocate for 
his

[[Page S9484]]

profession, and I am grateful for his lifetime contribution to treating 
blood diseases and advocating for biomedical research.

                          ____________________